VERTEX PHARMACEUTICALS INC / MA Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $144.94 per share as of 2022-12-31, per its 10-K filed 2023-02-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2023-02-10
- 2022-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $144.94.
- 2021-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $136.13.
- 2020-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $125.83.
- 2020-09-30: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $123.22.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2022-12-31 | $144.94 10-K · filed 2023-02-10 |
| 2021-12-31 | $136.13 10-K · filed 2022-02-09 |
| 2020-12-31 | $125.83 10-K · filed 2021-02-11 |
| 2020-09-30 | $123.22 10-Q · filed 2020-10-30 |
| 2020-06-30 | $121.00 10-Q · filed 2020-07-31 |
| 2020-03-31 | $119.05 10-Q · filed 2020-05-01 |
| 2019-12-31 | $114.15 10-K · filed 2020-02-13 |
| 2019-09-30 | $109.42 10-Q · filed 2019-10-31 |
| 2019-06-30 | $106.24 10-Q · filed 2019-08-01 |
| 2019-03-31 | $100.04 10-Q · filed 2019-05-01 |
| 2018-12-31 | $93.21 10-K · filed 2019-02-13 |
| 2018-09-30 | $89.83 10-Q · filed 2018-10-25 |
| 2018-06-30 | $87.14 10-Q · filed 2018-07-26 |
| 2018-03-31 | $84.36 10-Q · filed 2018-04-27 |
| 2017-12-31 | $80.14 10-K · filed 2018-02-15 |
| 2017-09-30 | $77.92 10-Q · filed 2017-10-30 |
| 2017-06-30 | $77.74 10-Q · filed 2017-07-28 |
| 2017-03-31 | $71.52 10-Q · filed 2017-04-28 |
| 2016-12-31 | $68.92 10-K · filed 2017-02-23 |
| 2016-09-30 | $66.29 10-Q · filed 2016-10-31 |
| 2016-06-30 | $63.32 10-Q · filed 2016-08-01 |
| 2016-03-31 | $59.71 10-Q · filed 2016-05-03 |
| 2015-12-31 | $56.85 10-K · filed 2016-02-16 |
| 2015-09-30 | $53.98 10-Q · filed 2015-10-30 |
| 2015-06-30 | $52.06 10-Q · filed 2015-08-04 |
| 2015-03-31 | $47.36 10-Q · filed 2015-05-04 |
| 2014-12-31 | $45.61 10-K · filed 2015-02-13 |
| 2014-09-30 | $43.53 10-Q · filed 2014-11-06 |
| 2014-06-30 | $41.65 10-Q · filed 2014-07-31 |
| 2014-03-31 | $39.60 10-Q · filed 2014-05-05 |
| 2013-12-31 | $38.84 10-K · filed 2014-02-11 |
| 2013-09-30 | $37.87 10-Q · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |